This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Autism Patients Could Be Helped with Cannabis

Stocks in this article: GWPH

NEW YORK (TheStreet) -- Analysts may be underestimating the potential of GW Pharmaceuticals (GWPH). Five analysts are covering the company, the most recent initiation coming from Morgan Stanley. The average price target is $86 and the stock currently trades at $71.

GW Pharmaceuticals is known for its flagship drug Sativex, which combines both the THC and the CBD extracts from the cannabis plant for medicinal purposes. Sativex is delivered as a mouth spray and has been approved for use in countries like Great Britain, Canada and Germany to name a few. It is considered to be the only mainstream pharmaceutical company to pursue cannabis testing and scientific trials. Solvay Pharmaceuticals produces Marinol, a THC only drug, which is approved by the FDA in the U.S. Solvay has done no studies since 2004.

The analysts are mostly excited about the use of GW's drug Epidiolex for pediatric epilepsy, specifically Dravet Syndrome and the patients that suffer from Lennox Gastaut syndrome. They are fairly small patient populations, roughly 5,000 Dravet patients in the U.S. and 15,000 LGS. However, there is little competition and the patients' needs are mostly unmet. So GW will own this market.

WATCH: More feature videos on TheStreet TV | More videos from Debra Borchardt

The bigger potential market for GW Pharmaceuticals could be autism. PiperJaffrey analyst Josh Schimmer has noted that subsets of these diseases share similar features with epilepsy. He writes, "It's possible that some children have subclinical seizure activity that result in developmental disorders, and there are also extremely exciting anecdotes of autism patients who thrive after CBD therapy." According to the Center for Disease Control and Prevention, 1.5% of the children in the U.S. are diagnosed with ASD as of 2014, a huge patient population.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs